NCT01388816View on ClinicalTrials.gov

A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Type II Hyperlipidemia
Interventions
DRUG

DRL-17822 or placebo

DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast

Trial Locations (12)

Unknown

Genova

Milan

Modena

Palermo

Perugia

Gdynia

Gniewkowo

Katowice

Wroclaw

Chernivtsi

Kharkiv

Kyiv

Sponsors

Collaborators (1)

PharmaNet
All Listed Sponsors
collaborator

PharmaNet

INDUSTRY

lead

Dr. Reddy's Laboratories Limited

INDUSTRY

NCT01388816 - A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels | Biotech Hunter | Biotech Hunter